Cerecor announced postitive data in phase 2 clinical trial in patients hospitalized with COVID-19 ARDS
On Mar. 2, 2021, Cerecor announced final efficacy data including 60-day mortality from their completed US-based, multi-center (10…
-
-
Biden administration announced collaboration between Merck and Johnson & Johnson to expand production of COVID-19 vaccines
On Mar. 2, 2021, Biden invoked the Defense Production Act to equip two Merck facilities to the standards necessary…
-
Colombia received the first vaccines arriving in the Americas through COVAX
On Mar. 1, 2021, Colombia became the first country in the Americas to receive COVID-19 vaccines through the…
-
COVID-19 can kill heart muscle cells, interfere with contraction
On Mar. 1, 2021, a study from Washington University School of Medicine in St. Louis provided evidence that…
-
Biotechnology | COVID-19 | FDA
Quidel received Emergency Use Authorization for QuickVue at-home COVID-19 test
On Mar. 1, 2021, Quidel announced that it had received an Emergency Use Authorization (EUA) from the FDA,…
-
First COVID-19 COVAX vaccine doses administered in Africa
On Mar. 1, 2021, the World Health Organization (WHO) announced that the first COVID-19 vaccination campaigns in Africa using…
-
CDC’s ACIP issued interim recommendation for use of Janssen COVID-19 vaccine
On Feb. 28, 2021, after a transparent evidence-based review of all available data, the Advisory Committee on Immunization…
-
CDC Advisory Committee recommended single-shot COVID-19 vaccine for adults 18 and older in US
On Feb. 28, 2021, Johnson & Johnson announced that the U.S. Centers for Disease Control and Preventionﾒs (CDC)…
-
Johnson & Johnson single-shot COVID-19 vaccine authorized by US FDA for Emergency Use
On Feb. 27, 2021, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) had issued…
-
Roche SARS-CoV-2 rapid rntigen test received special approval for at-home patient self-testing in Germany
On Feb. 26, 2021, Roche announced it had been granted special approval by the German Federal Institute for…
-
Innovation Pharma provided study details for phase 2 clinical trial of Brilacidin in hospitalized COVID-19 patients
On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee…
-
Novavax and Takeda finalized license agreement for Novavax COVID-19 vaccine candidate in Japan
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
-
Johnson & Johnson COVID-19 vaccine candidate recommended for EUA by FDA advisory committee
On Feb. 26, 2021, Johnson & Johnson announced that the FDA Vaccines and Related Biological Products Advisory Committee…
-
EMA accepted Pfizerﾒs MAA for investigational 20-valent pneumococcal conjugate vaccine
On Feb. 26, 2021, Pfizer announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization…
-
EMA issued advice on Regeneron’s antibody cocktail (casirivimab with imdevimab) for COVID-19 patients
On Feb. 26, 2021, Regeneron announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
-
Biotechnology | Disease | FDA | Genomics | Therapeutics
FDA approved targeted treatment for rare Duchenne muscular dystrophy mutation
On Feb. 25, 2021, the U.S. Food and Drug Administration (FDA) granted approval to Sarepta Therapeutics for Amondys…
-
FDA allowed more flexible storage, transportation conditions for Pfizer-BioNTech COVID-19 vaccine
On Feb. 25, 2021, the U.S. Food and Drug Administration announced that it was allowing undiluted frozen vials…
-
Altimmune commenced enrollment in phase 1 trial of AdCOVID needle-free, single-dose Intranasal COVID-19 vaccine candidate
On Feb. 25, 2021, Altimmune announced that it had commenced enrollment in a Phase 1 clinical trial of…
-
Chimerix reported promising topline results from first cohort of a randomized COVID-19 trial with DSTAT
On Feb. 25, 2021, Chimerix reported topline results from the first cohort of its randomized, double-blind, placebo-controlled Phase…
-
IDMC found clear efficacy for REGEN-COVﾙ in phase 3 COVID-19 outpatient outcomes trial
On Feb. 25, 2021, Regeneron announced changes to the phase 3 trial assessing investigational REGEN-COVﾙ (casirivimab with imdevimab)…
-
Pfizer and BioNTech initiated sudy to evaluate COVID-19 booster and new vaccine variants
On Feb. 25, 2021, Pfizer and BioNTech announced they had begun an evaluation of the safety and immunogenicity…
-
UTSW researchers identified mechanism by which exercise strengthens bones and immunity
On Feb. 25, 2021, scientists at the Childrenﾒs Medical Center Research Institute at UT Southwestern announced they had…
-
Overall deaths did not increase for most Chinese regions during the initial COVID-19 outbreak
On Feb. 24, 2021, scientists at the University of Oxford reported that overall deaths did not increase in…
-
COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marked beginning of global rollout
On Feb. 24, 2021, Ghana became the first country outside India to receive COVID-19 vaccine doses shipped via…
-
NeuroRx announced that ZYESAMI (Aviptadil) had successfully demonstrated accelerated recovery from Covid-19 respiratory failure
On Feb. 24, 2021, NeuroRx, announced that the phase 2b/3 trial of ZYESAMI for the treatment of Respiratory…
-
XPhyto placed first order for 25-minute COVID-19 RT-PCR tests
On Feb. 24, 2021, XPhyto announced that it has placed the first order for its rapid point-of-care SARS-CoV-2…
-
Quest Diagnostics introduced new COVID-19 semi-quantitative serology test service
On Feb. 24, 2021, Quest Diagnostics introduced a new COVID-19 testing service that aids in providing insight into…
-
Monoclonal antibodies against MERS Coronavirus showed promise in phase 1 NIH-sponsored trial
On Feb. 23, 2021, the NIH announced that a randomized, placebo-controlled Phase 1 clinical trial of two monoclonal…
-
Cue received CE Mark for Its molecular point-of-care COVID-19 test
On Feb. 23, 2021, Cue Health announced that its molecular point-of-care COVID-19 Test had received the CE mark,…
-
PerkinElmer changed COVID-19 rapid testing with highly sensitive point of care antigen test for mass screening
On Feb. 23, 2021, PerkinElmer announced the launch of the PerkinElmerﾮ COVID-19 Antigen Test for the qualitative detection…
